Derek T O'Hagan

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. doi request reprint The path to a successful vaccine adjuvant--'the long and winding road'
    Derek T O'Hagan
    Novartis Vaccines, Cambridge, MA 02139, USA
    Drug Discov Today 14:541-51. 2009
  2. doi request reprint The history of MF59(®) adjuvant: a phoenix that arose from the ashes
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Expert Rev Vaccines 12:13-30. 2013
  3. doi request reprint The mechanism of action of MF59 - an innately attractive adjuvant formulation
    D T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, United States
    Vaccine 30:4341-8. 2012
  4. doi request reprint MF59 adjuvant: the best insurance against influenza strain diversity
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Expert Rev Vaccines 10:447-62. 2011
  5. ncbi request reprint MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 6:699-710. 2007
  6. ncbi request reprint MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    D T O'Hagan
    Novartis Vaccines and Diagnostics Inc, Siena, Italy
    Clin Pharmacol Ther 82:740-4. 2007
  7. doi request reprint MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)
    Barbara C Baudner
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Pharm Res 26:1477-85. 2009
  8. doi request reprint MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine
    Manmohan Singh
    Novartis Vaccines, Cambridge, MA, USA
    Hum Vaccin Immunother 8:486-90. 2012
  9. doi request reprint Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant
    Mildred Ugozzoli
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Anal Biochem 418:224-30. 2011
  10. doi request reprint Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
    Samuele Calabro
    Novartis Vaccines and Diagnostics, Siena, Italy
    Vaccine 29:1812-23. 2011

Collaborators

Detail Information

Publications31

  1. doi request reprint The path to a successful vaccine adjuvant--'the long and winding road'
    Derek T O'Hagan
    Novartis Vaccines, Cambridge, MA 02139, USA
    Drug Discov Today 14:541-51. 2009
    ..In combination with data showing the positive contributions of the adjuvants to the immune response, this safety data should allow several vaccines containing novel adjuvants to obtain licensure within the next few years...
  2. doi request reprint The history of MF59(®) adjuvant: a phoenix that arose from the ashes
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Expert Rev Vaccines 12:13-30. 2013
    ..Even when safety issues have emerged for alternative adjuvants, careful analysis of the substantial safety database for MF59 have shown that there are no significant concerns with widespread use, even in more 'sensitive' populations...
  3. doi request reprint The mechanism of action of MF59 - an innately attractive adjuvant formulation
    D T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, United States
    Vaccine 30:4341-8. 2012
    ..This recruitment appears to be triggered by the induction of a chemokine driven gradient by the impact of MF59 on local cells, which are activated to secrete further chemokines, which are recruitment factors for more immune cells...
  4. doi request reprint MF59 adjuvant: the best insurance against influenza strain diversity
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Expert Rev Vaccines 10:447-62. 2011
    ....
  5. ncbi request reprint MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 6:699-710. 2007
    ..MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types...
  6. ncbi request reprint MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    D T O'Hagan
    Novartis Vaccines and Diagnostics Inc, Siena, Italy
    Clin Pharmacol Ther 82:740-4. 2007
    ..The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately...
  7. doi request reprint MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)
    Barbara C Baudner
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Pharm Res 26:1477-85. 2009
    ..Its ability to enhance antibody titres and to modulate the quality of the immune response to a subunit influenza vaccine was investigated...
  8. doi request reprint MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine
    Manmohan Singh
    Novartis Vaccines, Cambridge, MA, USA
    Hum Vaccin Immunother 8:486-90. 2012
    ..The delivery of TLR4 agonist within MF59 emulsion oil droplets leads to a more potent response in comparison to the TLR4 when admixed with MF59 emulsion...
  9. doi request reprint Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant
    Mildred Ugozzoli
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Anal Biochem 418:224-30. 2011
    ..We believe that this novel FC-based assay could circumvent some of the complex and tedious antigen-adjuvant desorption methods...
  10. doi request reprint Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
    Samuele Calabro
    Novartis Vaccines and Diagnostics, Siena, Italy
    Vaccine 29:1812-23. 2011
    ..Further studies will reveal whether other single cell types are crucial or whether the different recruited cell populations are redundant with overlapping functions...
  11. doi request reprint The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant
    Siddhartha Jain
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Expert Rev Vaccines 10:1731-42. 2011
    ..With strategic development of PLG-based vaccines, PLG microparticles can offer advantages over the conventional vaccine adjuvants allowing commercial development of this adjuvant...
  12. doi request reprint An alternative renewable source of squalene for use in emulsion adjuvants
    Luis A Brito
    Novartis Vaccines and Diagnostics, 350 Massachusetts Ave, Cambridge, MA 02139, USA
    Vaccine 29:6262-8. 2011
    ..Results indicate that there are no differences between the antibodies elicited after immunization from an emulsion made with oil derived from either an animal or plant-source...
  13. ncbi request reprint Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
    Andreas Wack
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Vaccine 26:552-61. 2008
    ..These observations have significant implications for the development of new and improved flu vaccines against pandemic and inter-pandemic influenza virus strains...
  14. doi request reprint Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens
    Sushma Kommareddy
    Vaccines Research, Novartis Vaccines, Cambridge, Massachusetts, USA
    J Pharm Sci 101:1021-7. 2012
    ..1 and 1 μg and trivalent vaccine at a dose of 1 μg. The initial data from the mouse studies is promising and indicates the potential use of microneedle technology for the delivery of influenza vaccine...
  15. doi request reprint The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect
    Samuele Calabro
    Novartis Vaccines and Diagnostics Research Center, Via Fiorentina 1, I 53100 Siena, Italy
    Vaccine 31:3363-9. 2013
    ..These observations may have important implications in the design of optimal emulsion-based vaccine adjuvants. ..
  16. doi request reprint Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations
    Simone Vecchi
    Novartis Vaccines and Diagnostics, Siena 53100, Italy
    J Pharm Sci 101:17-20. 2012
    ..A table with conversion factors is included in order to provide a tool for calculation of doses with different Al salts...
  17. doi request reprint A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery
    Siddhartha Jain
    Novartis Vaccines and Diagnostics, Cambridge, Massachusetts 02139, USA
    J Pharm Sci 100:646-54. 2011
    ..This approach may enable the use of PLG formulations with a variety of antigens and stockpiling for pandemics...
  18. doi request reprint Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles
    Padma Malyala
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Adv Drug Deliv Rev 61:218-25. 2009
    ..We will also discuss the advantages and enhancement of immune properties of formulating CpG (soluble, adsorbed, and encapsulated forms) with PLG microparticles along with future directions for these microparticles with CpG...
  19. pmc Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
    Anja Seubert
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 108:11169-74. 2011
    ..Because MF59 did not activate any of the Toll-like receptors in vitro, we propose that MF59 requires MyD88 for a Toll-like receptor-independent signaling pathway...
  20. ncbi request reprint The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells
    Anja Seubert
    Novartis Vaccines, Siena, Italy
    J Immunol 180:5402-12. 2008
    ....
  21. doi request reprint Immunology of TLR-independent vaccine adjuvants
    Ennio De Gregorio
    Novartis Vaccines and Diagnostics, Siena, Italy
    Curr Opin Immunol 21:339-45. 2009
    ..These findings highlight that the activation of DCs plays a central role in the mechanism of action of all classes of vaccine adjuvants but can occur by a multitude of different pathways and cellular interactions...
  22. doi request reprint Alum adjuvanticity: unraveling a century old mystery
    Ennio De Gregorio
    Department of Immunology, Novartis Vaccines and Diagnostics, Siena, Italy
    Eur J Immunol 38:2068-71. 2008
    ..Surprisingly, these three studies reported conflicting results on the requirement of the Nlrp3 inflammasome complex for alum adjuvant effects in vivo. This commentary attempts to resolve some of these discrepancies...
  23. doi request reprint Mechanism of action of licensed vaccine adjuvants
    Elaine Tritto
    Novartis Vaccines and Diagnostics, Via Fiorentina, 1 53100 Siena, Italy
    Vaccine 27:3331-4. 2009
    ..More work needs to be performed to investigate if the inflammasome is also required for the activity of MF59 and of other particulate vaccine adjuvants...
  24. doi request reprint Vaccine adjuvant formulations: A pharmaceutical perspective
    Luis A Brito
    Novartis Vaccines, Cambridge, MA, USA
    Semin Immunol 25:130-45. 2013
    ..As antigen and adjuvant formulations increase in complexity having a well characterized robust formulation will be critical to ensuring robust and reproducible results throughout preclinical and clinical studies. ..
  25. pmc Nonviral delivery of self-amplifying RNA vaccines
    Andrew J Geall
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 109:14604-9. 2012
    ..Given the many positive attributes of nucleic acid vaccines, our results suggest that a comprehensive evaluation of nonviral technologies to deliver self-amplifying RNA vaccines is warranted...
  26. pmc Combination vaccines
    David Ag Skibinski
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    J Glob Infect Dis 3:63-72. 2011
    ..Here, we review these challenges and also discuss future prospects for combination vaccines...
  27. doi request reprint Bioadhesive delivery systems for mucosal vaccine delivery
    Barbara C Baudner
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena, Italy
    J Drug Target 18:752-70. 2010
    ..In addition, careful consideration is needed to define the "best" route for mucosal immunization for each individual pathogen...
  28. doi request reprint Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung
    Isabella Pesce
    Department of Immunology, Novartis Vaccines Research Center, Siena, Italy
    J Innate Immun 2:144-59. 2010
    ....
  29. pmc Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists
    Mirela Kuka
    Novartis Vaccines, Siena, Italy
    PLoS ONE 5:e11491. 2010
    ..It was previously shown by our group that Src kinases play a key role in cytokines production during TLR4 activation in human DC...
  30. doi request reprint New adjuvants for human vaccines
    M Lamine Mbow
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Curr Opin Immunol 22:411-6. 2010
    ..This review highlights recent progress of clinically approved vaccine adjuvants and identifies potential novel adjuvants that can broaden the development of new vaccines against infectious diseases...
  31. ncbi request reprint The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature
    Elaine Tritto
    Novartis Vaccines and Diagnostics, Siena, Italy
    J Immunol 179:5346-57. 2007
    ..Our data suggest that LTK63 acts as an airway infection mimic that establishes a generic protective environment limiting respiratory infection by innate immune mechanisms and by improving adaptive responses to invading pathogens...